Sorrento becomes one-stop ADC shop with $11.6m Concortis buy
This article was originally published in Scrip
The recent spending spree by Sorrento Therapeutics has come to an end with the acquisition of Concortis BioSystems whose linkers and cytotoxic agents will be combined with antibodies from Sorrento's G-MAB library to create a one-stop antibody-drug conjugate (ADC) shop.
You may also be interested in...
Managing partner Corey Goodman said venBio didn’t have trouble closing its fund, because the venture capital firm prepared its investors for an economic downturn months ago.
Flagship Pioneering raised $1.1bn to fund life science companies emerging from Flagship Labs. ARCH, another frequent start-up co-founder, raised two funds totaling $1.46bn to back early-stage biotech.
Aspen Neuroscience, Pandion and iTeos raised $70m, $80m and $125m, respectively. Also, Glide Healthcare closed a €416m ($450m) fund; ElevateBio, Kallyope and SutroVax reveal VC mega-rounds; and Dragonfly adds new funding to its partnering proceeds.